Do you want to read an article? Please log in or register.
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
Eur Urol
Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP
doi: 10.1016/j.eururo.2025.04.017
COMMENTED
Genitourinary Cancer
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110
Genitourinary Cancer
Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide
Prostate
Martínez Osorio CA, Sopeña Sutil R, Vilaseca Cabo A, Linares Espinós E, Ramírez Backhaus M, Gómez Rivas J, Costa Planells M, Martinez Breijo S, Picola Brau N, Domínguez Esteban N, Muñoz Rodríguez J, Sanchís Bonet A, Guijarro Cascales A, Beamud Cortés M, Servian Vives P, de la Morena Gallego JM, Pérez Márquez M, García Sanz M, Ramón Alemán J, Zamora Horcajada Á, Rodríguez Part V, Hassi Roman M, Rodriguez Concha C, Rios González E, de Pablos-Rodríguez P
doi: 10.1002/pros.70040
Genitourinary Cancer
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Eur Urol Oncol
Wallis CJD, Ekberg S, Morgans AK, Boegemann M, Paracha N, Gallagher E, Crowther MJ, Shore N
doi: 10.1016/j.euo.2025.03.001
Genitourinary Cancer
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Prostate Cancer Prostatic Dis
Yu EY, Suzuki H, Pieczonka CM, Gotto G, Briganti A, Luz M, Murphy D, Malone R, Hamilton J, Chan JE, Sieber P, Given RW, Hellmis E, Kretz T, Spiegelhalder P, Gómez-Caamaño A, Amela YM, Artignan X, Uemura H, Fujita N, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ
doi: 10.1038/s41391-025-01047-7
Genitourinary Cancer
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry
Eur Urol
Karpinski MJ, Hoberück S, Fendler WP, Civan C, Bundschuh RA, Thomas C, Bjartell A, Trägårdh E, Soeterik TFW, Evangelista L, Vondrak A, Rasul S, Forner L, Giorgio AD, Scholtissek H, Miksch J, Holzgreve A, Lanfranchi F, Rahbar K, Hofman MS, Rauscher I, Güven O, Eiber M, Ayati N, Umutlu L, Herrmann K, Hadaschik B, Emmett L
doi: 10.1016/j.eururo.2025.10.013
Genitourinary Cancer
Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Lancet Oncol
Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O
doi: 10.1016/S1470-2045(25)00189-5
Genitourinary Cancer
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial
Eur Urol
Vigneswaran HT, Palsdottir T, Micoli C, Tilki D, Lin D, Cooperberg M, Eggener S, Falagario UG, Möller A, Aly M, Akre O, Wiklund P, Egevad L, Grönberg H, Nordström T, Eklund M
doi: 10.1016/j.eururo.2025.10.001
Genitourinary Cancer
Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study
Adv Ther
Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, Chilelli A, Stoelzel M, Serikoff A, Spitzer SG
doi: 10.1007/s12325-025-03132-8